215 results
8-K
EX-99.4
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
) to June 30, 2024, net cash used in operating activities was $11.2 million, which was primarily attributable to a net loss of $29.3 million, offset … payable and other current liabilities, $1.0 million increase in accrued interest, related party, partially offset by a $1.7 million increase in prepaid
424B3
ORKA
Oruka Therapeutics Inc.
1 Aug 24
Prospectus supplement
4:10pm
. tax expense.
Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.
As of December 31 … credits that may be used to offset future taxable income. We had net operating loss carryforwards of $156.4 million generated prior to 2018, which
425
26dvrangx0f8et5bie2g
25 Apr 24
Business combination disclosure
4:27pm
8-K
EX-99.1
6gm4w29q11
25 Apr 24
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
4:25pm
8-K
EX-99.1
gsk9qwlwggyxz4pamei
1 Feb 24
ARCA biopharma Announces 2023 Financial Results
4:39pm
8-K
EX-99.1
ekv inwh6rih
28 Oct 22
ARCA biopharma Announces Third Quarter 2022 Financial Results
4:25pm
8-K
EX-99.1
dza0w
2 May 22
ARCA biopharma Announces First Quarter 2022 Financial Results
4:23pm